DNTH - Dianthus Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$115.00
DETAILS
HIGH:
$145.00
LOW:
$55.00
MEDIAN:
$120.00
CONSENSUS:
$115.00
UPSIDE:
8.78%
About Dianthus Therapeutics, Inc. (https://dianthustx.com)
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Marino Garcia | President, Chief Executive Officer & Director | 1966 | $1,163,750 USD |
| Simrat Randhawa | Executive Vice President and Head of R&D | 1970 | $932,680 USD |
| Ryan Savitz | Executive VP, CFO, Chief Business Officer & Treasurer | 1989 | $786,096 USD |
| Adam Veness | Senior Vice President, General Counsel & Secretary | 1986 | – |
| Edward G. Carr | Senior VP & Chief Accounting Officer | 1969 | – |
| Jennifer Davis Ruff | Vice President and Head of Investor Relations & Corporate Affairs. | – | – |
| Judson Taylor | Senior Vice President & Head of Technical Operations | – | – |
| Kristina Maximenko | Chief People Officer | – | – |
| Rashieda Gluck | Head of Clinical Development Operations | – | – |
| Scott Nogi | Head of Business Operations | – | – |